Clearside Biomedical (CLM0) Stock Overview
A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CLM0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Clearside Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.98 |
| 52 Week High | US$2.98 |
| 52 Week Low | US$2.98 |
| Beta | 1.79 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
Shareholder Returns
| CLM0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 6.9% | 0.2% |
| 1Y | n/a | -2.2% | 13.2% |
Return vs Industry: Insufficient data to determine how CLM0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CLM0 performed against the German Market.
Price Volatility
| CLM0 volatility | |
|---|---|
| CLM0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CLM0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine CLM0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 32 | George Lasezkay | clearsidebio.com |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD.
Clearside Biomedical, Inc. Fundamentals Summary
| CLM0 fundamental statistics | |
|---|---|
| Market cap | €17.24m |
| Earnings (TTM) | -€22.41m |
| Revenue (TTM) | €2.87m |
Is CLM0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLM0 income statement (TTM) | |
|---|---|
| Revenue | US$3.33m |
| Cost of Revenue | US$397.00k |
| Gross Profit | US$2.93m |
| Other Expenses | US$28.93m |
| Earnings | -US$26.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.97 |
| Gross Margin | 88.07% |
| Net Profit Margin | -780.90% |
| Debt/Equity Ratio | -113.4% |
How did CLM0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 02:28 |
| End of Day Share Price | 2025/09/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clearside Biomedical, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Donald Ellis | Citizens JMP Securities, LLC |
| Jonathan Wolleben | Citizens JMP Securities, LLC |